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Trial DesignProbing oral anticoagulation in patients with
atrial high rate episodes: Rationale and
design of the Non–vitamin K antagonist Oral
anticoagulants in patients with Atrial High
rate episodes (NOAH–AFNET 6) trial
PaulusKirchhof,MD,a,b,c,d,e BenjaminF.BlankdMelanieCalvert,PhD,e,f A. JohnCamm,MD,gGregoryChlouverakis,PhD,h
Hans-Christoph Diener, MD, i Andreas Goette, MD, d,j Andrea Huening, MD, k Gregory Y. H. Lip, MD, a,b,l
Emmanuel Simantirakis, MD,m and Panos Vardas, MDm Birmingham, London, United Kingdom; Muenster, Essen,
Paderborn, Munich, Germany; Crete, Greece; and Aalborg, DenmarkBackground Oral anticoagulation prevents ischemic strokes in patients with atrial fibrillation (AF). Early detection of AF and
subsequent initiation of oral anticoagulation help to prevent strokes in AF patients. Implanted cardiac pacemakers and defibrillators
allow seamless detection of atrial high rate episodes (AHRE), but the best antithrombotic therapy in patients with AHRE is not known.
Rationale Stroke risk is higher in pacemaker patients with AHRE than in those without, but the available data also show that
stroke risk in patientswithAHRE is lower than in patientswithAF. Furthermore, only aminority of patientswithAHREwill developAF,
many strokes occurwithout a temporal relation toAHRE, andAHRE can reflect other arrhythmias thanAF or artifacts. An adequately
powered controlled trial of oral anticoagulation in patients with AHRE is needed.
Design TheNon–vitamin K antagonistOral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6 ) trial tests
whether oral anticoagulationwith edoxaban is superior toprevent theprimaryefficacyoutcomeof strokeor cardiovascular death compared
withaspirinornoantithrombotic therapybasedonevidence-based indications. Theprimary safetyoutcomewill bemajorbleeding.NOAH–
AFNET 6will randomize 3,400 patients with AHRE, but without documented AF, aged ≥65 years with at least 1 other stroke risk factor, to
oral anticoagulation therapy (edoxaban) or no anticoagulation. All patients will be followed until the end of this investigator-driven,
prospective, parallel-group, randomized, event-driven, double-blind,multicenter phase IIIb trial. Patientswill be censoredwhen theydevelop
AF and offered open-label anticoagulation. The sponsor is the Atrial Fibrillation NETwork (AFNET). The trial is supported by the DZHK
(German Centre for Cardiovascular Research), the BMBF (German Ministry of Education and Research), and Daiichi Sankyo Europe.
Conclusion NOAH–AFNET 6 will provide robust information on the effect of oral anticoagulation in patients with atrial
high rate episodes detected by implanted devices. (Am Heart J 2017;190:12-18.)Background and rationale
Atrial fibrillation (AF) is a common cause of stroke,
especially ischemic stroke. Unlike strokes of other major
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introduced into clinical practice as alternatives to vitamin
K antagonist (VKA) therapy.4-8 NOACs provide similaresearch Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, and
Department of Cardiology, Heraklion University Hospital, Crete, Greece.
CT# NCT02618577
ubmitted February 13, 2017; accepted April 29, 2017.
eprint requests: Paulus Kirchhof, Institute of Cardiovascular Sciences, University of
irmingham, Birmingham, United Kingdom.
-mail: p.kirchhof@bham.ac.uk
002-8703
2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC
Y license (http://creativecommons.org/licenses/by/4.0/).
ttp://dx.doi.org/10.1016/j.ahj.2017.04.015R
m
R
S
R
B
E
0
©
B
h
Kirchhof et al 13
American Heart Journal
Volume 190, Number 0stroke prevention efficacy and are at least as safe as
VKA,8,9 with less intracranial hemorrhage and a 10%
reduction in mortality in the pivotal trials.10
So far, all available data that demonstrate a beneficial
effect of oral anticoagulation for stroke prevention have
been collected in populations with AF documented by
conventional electrocardiogram (ECG).2,3 Studies in other
populations in the absence of AF, for example, heart failure
or survivors of a stroke, had overall neutral outcomes,
where slight reductions in strokewere counterbalanced by
increased bleeding.11,12 Therefore, antiplatelet therapy is
recommended for secondary prevention of ischemic
strokes in patients without AF or other cardioembolic
cause of stroke.
Many AF episodes remain undiagnosed.2,3 Often, a
potentially preventable stroke is the first clinical manifes-
tation of hitherto undetected AF (silent AF). In fact, around
5% of unselected patients presenting with an acute stroke
suffer from silent AF that is detected by a simple ECG upon
admission.13,14 Published and ongoing studies suggest
that systematic ECG screening using patient-operated
devices15-17 or “opportunistic screening” in those present-
ing to a health care professional18 can detect silent AF. This
is in line with predictions made from trial data sets.19
Systematic ECG monitoring in stroke survivors detects
silent paroxysmal AF in approximately 5% of unselected
stroke patients13,20 and in up to 20% when long-term ECG
monitoring is applied to patients with cryptogenic
stroke.21-23 Even these prolonged ECG monitoring tech-
niques will miss silent AF in many patients.19 Continuous
monitoring of atrial rhythm could close this diagnostic gap,
19 requiring implanted devices and automated or semiau-
tomated analysis.21-23
Most modern pacemakers, defibrillators, and cardiac
resynchronization devices provide automated algo-
rithms alerting to the occurrence of atrial high rate
episodes, also called subclinical atrial fibrillation or,
more appropriately, device-detected atrial high rate
episodes (AHRE).2,24,25 Data from large prospectively
followed patient cohorts have demonstrated that the
presence of AHRE increases stroke risk.24,26,27 Only a
minority of patients with AHRE (estimated at 13%-16%
over 2.5 years) will develop AF.24,28
The absolute stroke rates are lower in patients with
AHRE when compared with stroke rates in patients with
clinically diagnosed AF.24,26,27,29,30 For example, the
TRENDS cohort, collecting information on patients with
long AHRE episodes, reported a stroke rate of 1.1%-2.2%
per year.30 One of the largest cohorts, SOS, reported
AHRE and stroke rates in N10,000 unselected device
patients (mean age 70 years, more than 50% with
additional stroke risk factors, 80% not anticoagulated).27
AHRE were found in 43% of all patients. The annual rate
of stroke or transient ischemic attack was between 0.32%
and 0.67% per year. Stroke rates of around 1.7% per year
were reported in patients with AHRE enrolled into theASSERT24 and IMPACT trials.31 Higher stroke rates were
reported in other smaller and earlier series (Table II). The
SOS data set did not show a clear increase in patients with
higher AHRE burden (Figure 3 in Boriani et al27). Other
analyses in smaller populations have suggested that
longer AHRE episodes (eg, those lasting N24 hours) are
associated with a higher stroke risk.32,33 Furthermore,
automated detection algorithms of AHRE by implanted
devices have a good sensitivity, but their specificity may not
be optimal, especially for short episodes,34 to constantly
distinguish AF from other arrhythmias or artifacts.25,35 As an
illustrative example, 15% (19/130) patients without AF on a
simultaneously recorded Holter ECG were classified as
having AF on an implanted loop recorder.34 In summary,
stroke rates in patients with AHRE are often close to the
threshold for a net clinical benefit of NOAC therapy2 and
appear lower than the stroke rates found in patients with
paroxysmal AF detected by ECG.5,36,37
Also, only a minority of ischemic strokes in pacemaker
patients with AHRE occur in relation to the time of an AHRE
episode.24,27,30,31,38-40 Thus, there are important uncer-
tainties regarding the prognostic and therapeutic implica-
tions of device-detected AHRE (Text box). Reacting to these
uncertainties, several groups have proposed to evaluate
intermittent oral anticoagulation in AHRE patients.31,41 One
prior study (IMPACT) did not find a benefit of intermittent
oral anticoagulation compared with no anticoagulation in
2,718AHREpatients.31 In light of thebleeding complications
associatedwith oral anticoagulation,42-45 patientswith AHRE
should currently only be anticoagulated once AF has been
documented by ECG,46-48 a resource-intensive and
time-consuming process.2,25 A sufficiently powered ran-
domized trial of continuous oral anticoagulation compared
with no anticoagulation is needed to inform optimal stroke
prevention in AHRE patients.
Text box
Current uncertainties relating to the detection of AHRE
and to the management of patients with AHRE
1. The prognostic impact (eg, increase in stroke risk)
of rare and short episodes of atrial fibrillation or
other atrial arrhythmias documented onCIED logs,
often only a few hours per year, is probably lower
than that of ECG-diagnosed atrial fibrillation
2. Some AHRE reflect other atrial arrhythmias
than atrial fibrillation that do not require oral
anticoagulation for stroke prevention
3. The timing of AHRE is not closely related to strokes
observed in patients with AHRE, suggesting that
other mechanisms than cardioembolic stroke
underlie these events
4. AHRE episodes may be artifacts, especially those of
shorter duration.
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oagulants in patients with Atrial High rate episodes trial
Hypothesis. The Non–vitamin K antagonist Oral
anticoagulants in patients with Atrial High rate episodes
(NOAH–AFNET 6) trial tests the hypothesis that oral
anticoagulation with the NOAC edoxaban is superior to
current therapy (antiplatelet therapy or no therapy
depending on cardiovascular risk) to prevent stroke,
systemic embolism, or cardiovascular death in patients
with AHRE, but without AF, and with at least 2 stroke risk
factors. We will also assess whether the intervention
improves quality of life and maintains cognitive function.
NOAH–AFNET 6 is registered at clinicaltrials.gov
(NCT02618577), EudraCT (2015-003997-33), and
ISRCTN (17309850). The protocol was developed in
accordance with the Standard Protocol Items for
Randomized Trials statement49 and guidance from the
International Society for Quality of Life Research Best
Practice task force.50,51 No funding other than the
sources mentioned in the acknowledgment was used to
support this work. The authors and the study sponsor,
AFNET, are solely responsible for the design and conduct
of this study, all study analyses, the drafting and editing of
the paper, and its final contents. Further information can
be obtained from the trial Web site: www.noah.af-net.eu.
Patient population
NOAH–AFNET 6 will enroll patients with AHRE but
without diagnosed AF or another accepted indication for
oral anticoagulation. Patients in the trial would qualify for
oral anticoagulation if they had diagnosed AF, approxi-
mated by an age of 65 years or more and presence of at
least 1 additional clinical stroke risk factor.2 The trial has
broad inclusion and exclusion criteria in line with a
simple trial that is close to clinical practice (see Table I for
details). It has been reported that approximately 1 of 7
(13%-16%) of patients with device-detected AHRE will
develop AF over a mean follow-up of 2.5 years.24,26
Patients will undergo ECG in 6-month intervals (at
baseline and during follow-up). Patients will be censored
at the time of developing AF and taken off study
medication, as they have an indication for oral antic-
oagulation. All patients will be followed up until the end
of the trial. To date, 118 sites have been initiated in 11
countries. One hundred thirty-one patients have been
randomized so far.
Trial organization
NOAH–AFNET 6 is an investigator-initiated, prospec-
tive, parallel-group, double-blind, randomized, multicen-
ter phase IIIb trial (Figure). Study patients will be
randomized to 1 of 2 parallel groups in a 1:1 design,
designated as NOAC and Usual Care. Randomization will
be stratified by indication for use of antiplatelet therapy as
assessed by the responsible site investigator at the time ofrandomization. Patients randomized to the NOAC group
will receive edoxaban in the therapeutic dose approved
for stroke prevention in AF, that is, 60 mg od with a
reduction of dose to 30 mg od in patients with impaired
renal function, low body weight, or receiving certain
glycoprotein P inhibitors. Patients randomized to usual
care will receive either placebo or aspirin depending on
established indications for aspirin therapy. NOAH–
AFNET 6 is a joint project of the Atrial Fibrillation
NETwork (AFNET) and of the European Society of
Cardiology. AFNET is sponsor of the trial. The study is
led by an academic steering committee and overseen by a
data safety and monitoring board. The trial will be
conducted with the help of a clinical research organiza-
tion, the Clinical Research Institute based in Munich.
NOAH–AFNET 6 is supported by Daiichi Sankyo
Europe; the DZHK (German Centre for Cardiovascular
Research); and the BMBF (German Ministry of Education
and Research, FKZ 81x2800110).
Outcome parameters. The primary outcome param-
eter of NOAH–AFNET 6 is a composite of stroke, systemic
embolism, or cardiovascular death, measured as the time
from randomization to the first occurrence of either of
these events. All events will be centrally adjudicated by an
independent committee. Secondary outcome parameters
include components of the primary outcome, all-cause
death, major bleeding events according to the ISTH
definitions, changes in quality of life assessed using the
EQ-5D and the Karnofsky scale,52 patient satisfaction
assessed by the modified European Heart Rhythm Associ-
ation Symptoms (mEHRA) score2,53 and PACT-Q,51,52 and
cognitive function assessed by the Montreal Cognitive
Assessment (MoCA) at 12 and 24 months compared with
baseline. Cost-effectiveness and health resource utilization
will be assessed. All AHRE episodeswill be reanalyzedby an
independent core laboratory based atMaastricht University
to verify whether AHRE data uploaded by trial sites fulfill
the requirements of the protocol as inclusion criteria. The
core laboratory also performs quality control and provides
feedback to trial sites regarding their uploadedAHRE data if
necessary. Prespecified exploratory analyses will include
markers identifying patients at high stroke risk, for
example, by duration or pattern of AHRE episodes, or
using blood/ECG analyses. All patients will be followed up
until the end of the trial.
Estimation of the event rate and effect size for the
primary outcome in the NOAH–AFNET 6 popula-
tion. To arrive at a reliable estimate of the control group
event rate in the NOAH–AFNET 6 patient population,
stroke/systemic embolism and cardiovascular death rates
in patients with AHRE in published series were compiled
(Table II). Based on this analysis, considering stroke and
death rates in nonanticoagulated patients with paroxysmal
AF2,5,36,37 and accounting for the variability in stroke rate
estimates in published series of patients with AHRE (Table II),
an annual stroke rate of 1.9% and an annual cardiovascular
Table I. Inclusion and exclusion criteria of the NOAH–AFNET 6 trial
Inclusion criteria Exclusion criteria
I1. Pacemaker or defibrillator implanted for any reason with feature
of detection of AHRE, implanted at least 2 m prior to randomization
E1. Any disease that limits life expectancy to less than 1 y
I2. AHRE detection feature activated E2. Participation in another controlled clinical trial, either within the
past 2 months or still ongoing
I3. AHRE (≥180 beats/min atrial rate and ≥6-min duration) documented
by the implanted device via its atrial lead and stored digitally
E3. Previous participation in the present trial NOAH–AFNET 6
I4. Age ≥65 y E4. Drug abuse or clinically manifest alcohol abuse
I5. In addition, at least 1 of the following cardiovascular conditions
- Age ≥75 y,
- Heart failure (clinically overt or LVEF b45%),
- Arterial hypertension (long-term treatment for hypertension,
estimated need for continuous antihypertensive therapy,
or resting blood pressure N145/90 mm Hg),
- Diabetes mellitus,
- Prior stroke or TIA, or
- Vascular disease (peripheral, carotid/cerebral, or aortic plaques on TEE).
E5. Any history of AF or atrial flutter or presence of AF at
baseline 12-lead ECG
I6. Provision of signed informed consent E6. Indication for oral anticoagulation (eg, deep venous thrombosis)
E7. Contraindication for oral anticoagulation in general
E8. Contraindication for edoxaban as stated in the current SmPC
E9. Indication for long-term antiplatelet therapy other than
acetylsalicylic acid, especially DAPT
E10. Acute coronary syndrome, coronary revascularization (PCI or
bypass surgery), or overt stroke within 30 d prior to randomization
E11. End stage renal disease (CrCl b15 mL/min)
The inclusion criteria I4 and I5 closely resemble the criteria of a CHA2DS2-VASc score of ≥2 in patients with diagnosed AF. Patients with a transient requirement for dual antiplatelet
therapy (DAPT, eg, after receiving a stent) will be eligible when the need for DAPT is no longer present.
LVEF, Left ventricular ejection fraction; TIA, transient ischemic attack; TEE, transesophageal echocardiogram; SmPC, summary of product characteristics; DAPT, dual-antiplatelet
therapy; PCI, percutaneous coronary intervention; CrCL, creatinine clearance.
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Volume 190, Number 0death rate of 3.3% are expected, or a rate of the primary
outcome of 5.3% per year. For the purpose of NOAH–AFNET
6, patients randomized to edoxaban are expected to have a
two-thirds lower rate of stroke or TIA5,54 and a 10% reduction
in cardiovascular death. The effect estimate for stroke
prevention is based on the effect size observed for stroke
prevention with VKA (warfarin) or a NOAC (apixaban)
compared with acetylsalicylic acid in patients with AF,5,36
assuming that edoxaban is at least as effective as dose-adjusted
warfarin in preventing strokes in AHRE patients. The effect
size for reduction in cardiovascular death is the point estimate
of reduction in cardiovascular deaths observed in the 4NOAC
trials comparedwithwarfarin.10 This conservative estimate is
based on the assumption that the mortality benefit of
edoxaban compared with no anticoagulation in NOAH–
AFNET 6 is not bigger than the mortality benefit of edoxaban
compared with dose-adjusted warfarin observed in
ENGAGE-TIMI 488 and in the other 3 NOAC trials.10 These
assumptions result in anestimatedevent rateof 0.62%peryear
for stroke and 3% for cardiovascular death. The expected
event rate in the edoxaban group in NOAH–AFNET 6 (3.62%
per year) is very similar to the observed rate of stroke or
cardiovascular death in those patients enrolled in ENGAGE
and randomized to edoxaban who match the NOAH–AFNET
6 inclusion criteria (3.45% per year, data on file).The potential benefit of oral anticoagulation in the
NOAH–AFNET 6 population will have to be weighed
against the bleeding risk associated with long-term NOAC
therapy (Table III). It is worthwhile to note the IMPACT
trial in this context: IMPACT did not find a benefit of
intermittent anticoagulation, initiated at the time of
device-detected AHRE and continued for 30 to 90 days
after documentation of the last AHRE event, to usual care
(no anticoagulation) in 2,718 patients with AHRE and a
median CHA2DS2-VASc score of 4.31 IMPACT observed
22 ischemic strokes and 41 major bleeding events,
illustrating the equipoise for anticoagulation in patients
with device-detected AHRE and stroke risk factors.
Sample size. Three thousand four hundred patients
will be randomized. Computation of sample size is based
on a hazard ratio of 0.68, accrual period of 27 months,
and minimum follow-up of 12 months. Specifically, it
assumes annual hazard rates of 5.3% for the standard
treatment group versus 3.62% for the NOAC group. This
is equivalent to median event-free survival of 13 years for
the standard treatment group versus 19 years for the
NOAC group. This effect size is considered realistic in
view of the effect of continuous oral anticoagulation in
patients with AF. The minimum number of events that
need to be observed to detect the aforementioned
Figure
Flowchart of NOAH–AFNET 6. In the setting of NOAH–AFNET 6, edoxaban 60 mg od is the NOAC of choice. The dose will be reduced to 30 mg
od (in accordance with the label for AF) in patients with one of the following characteristics: (1) impaired renal function (creatinine clearance 15-
50 mL/min); (2) low body weight (≤60 kg); or (3) patients receiving the glycoprotein P inhibitors ketoconazole, cyclosporine, erythromycin, or
dronedarone. In a double-blind design, established indications in the inclusion criteria for antiplatelet therapy will guide the use of blind aspirin or
blind placebo for the patients not receiving anticoagulation. Patients randomized to NOAC will not receive aspirin in addition. All patients will be
followed until the end of the trial for events. ECGs will be recorded at baseline and in 6-month intervals during follow-up.
Table II. Annualized rate of stroke and cardiovascular death in
patients with device-detected AHRE
Study/population Stroke Cardiovascular death Sum
ASSERT,24 261 pts, 2.5-y FU 1.7 2.9 4.5
MOST,26 160 pts, 2.25-y FU† 5 4.2 9.2
AT500,55 725 pts, 1.8-y FU† 3.6
Botto et al,56 223 pts, 1-y FU 3.2
TRENDS,30 1.4-y FU† 1.2
SOS,27 10,106 pts, 2.2-y FU⁎ 0.4-0.8
Event rates are given as percentage per year, split by stroke and cardiovascular death.
The sum of these 2 components provides a first estimate of the primary outcome rate.
All events are rounded to 1 decimal percentage point.
The table lists event rates that were available at the time of designing NOAH–AFNET 6.
⁎SOS included approximately 20% of anticoagulated patients. Death and bleeding
event rates are not reported.
†MOST, TRENDS, and AT500 included patients with atrial fibrillation diagnosed by
ECG, thereby probably enriching for patients at higher stroke risk.
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power, is 222. Given the accrual and follow-up periods, at
least 1,260 patients per group are needed for that number
of events during the trial duration. The hazard of
developing overt AF or of dropping out of the trial for
other reasons is assumed to be at 0.287 throughout the
trial, equivalent to 25% of patients being censored in the
first year and rising to 57% at the end of 3 years. This
number includes patients who will develop AF, for
example, detected by routine ECG during follow-up visits
or by ECG monitoring initiated at the study sites. Taking
this into account, the number of patients per group
increases to 1,700. To account for slight variation of trial
duration and variability between estimated and observed
event rates, the trial protocol includes an interim analysis
of the combined enrolment and event rates (blind to
random group), with the possibility to adapt sample size.
Conclusion
In summary, the optimal antithrombotic therapy in
patients with AHRE but without diagnosed AF cannot be
derived from existing data. The information gained from
NOAH–AFNET6 and from theARTESiA trial (NCT01938248)will provide sound evidence to guide the use of oral
anticoagulation in patients with device-detected AHRE and
possibly in patients with atrial arrhythmias documented by
other devices. The results have the potential to inform future
guidance on the management of patients with atrial
arrhythmias detected by implantable devices.
Table III. Comparison of published annualized ischemic and bleeding event rates in populations with diagnosed AF that otherwise resemble the
projected NOAH–AFNET 6 population
Stroke, systemic embolism,
or cardiovascular death
Fatal
bleeding
Hemorrhagic stroke plus other
intracranial hemorrhage
Major extracranial
hemorrhage
ENGAGE-TIMI 48 edoxaban 60 mg od
dosing regime8
3.85 0.20 0.39 2.65
AVERROES aspirin arm5 6.40 0.20 0.50 1.2⁎
BAFTA aspirin arm36 8.10 0.10 0.50 2.00
The chart shows major efficacy (stroke or cardiovascular death, red) and safety events (fatal bleeding, hemorrhagic stroke or intracranial hemorrhage, major extracranial bleeding) in
controlled trials comparing anticoagulation with aspirin and in the ENGAGE-TIMI48 trial evaluating edoxaban.
⁎ For the AVERROES acetylsalicylic acid group, only the AVERROES major bleeds are reported, although some of the “clinically relevant nonmajor bleeds” in AVERROES would have
been classified as “major” in BAFTA and ENGAGE.
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